Target Price | $240.58 |
Price | $150.19 |
Potential | 60.18% |
Number of Estimates | 26 |
26 Analysts have issued a price target Biogen 2025 . The average Biogen target price is $240.58. This is 60.18% higher than the current stock price. The highest price target is $342.00 127.71% , the lowest is $164.00 9.20% . | |
A rating was issued by 36 analysts: 21 Analysts recommend Biogen to buy, 15 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Biogen stock has an average upside potential 2025 of 60.18% . Most analysts recommend the Biogen stock at Purchase. |
30 Analysts have issued a sales forecast Biogen 2024 . The average Biogen sales estimate is $9.6b . This is 4.46% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $9.8b 5.66% , the lowest is $9.5b 2.48% .
This results in the following potential growth metrics:
2023 | $9.4b | 0.17% |
---|---|---|
2024 | $9.6b | 2.37% |
2025 | $9.5b | 1.48% |
2026 | $9.7b | 1.72% |
2027 | $10.0b | 3.47% |
2028 | $10.3b | 3.25% |
10 Analysts have issued an Biogen EBITDA forecast 2024. The average Biogen EBITDA estimate is $3.3b . This is 21.44% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $3.9b 43.63% , the lowest is $2.7b 1.83% .
This results in the following potential growth metrics and future EBITDA Margins:
2023 | $2.1b | 23.87% |
---|---|---|
2024 | $3.3b | 56.97% |
2025 | $3.5b | 4.14% |
2026 | $3.5b | 1.48% |
2027 | $4.3b | 21.83% |
2028 | $4.9b | 14.86% |
2023 | 22.58% | 23.74% |
---|---|---|
2024 | 34.62% | 53.34% |
2025 | 36.60% | 5.72% |
2026 | 36.51% | 0.25% |
2027 | 42.99% | 17.75% |
2028 | 47.82% | 11.24% |
12 Biogen Analysts have issued a net profit forecast 2024. The average Biogen net profit estimate is $1.8b . This is 14.01% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $2.4b 47.61% , the lowest is $1.6b 1.35% .
This results in the following potential growth metrics and future Net Margins:
2023 | $1.2b | 61.81% |
---|---|---|
2024 | $1.8b | 58.36% |
2025 | $2.1b | 16.34% |
2026 | $2.5b | 15.83% |
2027 | $2.8b | 14.89% |
2028 | $3.2b | 10.74% |
2023 | 12.33% | 61.74% |
---|---|---|
2024 | 19.08% | 54.73% |
2025 | 22.53% | 18.08% |
2026 | 25.65% | 13.85% |
2027 | 28.48% | 11.03% |
2028 | 30.55% | 7.27% |
12 Analysts have issued a Biogen forecast for earnings per share. The average Biogen <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is $12.62 . This is 14.00% higher than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is $16.34 47.61% , the lowest is $11.22 1.36% .
This results in the following potential growth metrics and future valuations:
2023 | $7.97 | 61.81% |
---|---|---|
2024 | $12.62 | 58.34% |
2025 | $14.68 | 16.32% |
2026 | $17.01 | 15.87% |
2027 | $19.54 | 14.87% |
2028 | $21.64 | 10.75% |
Current | 13.67 | 46.71% |
---|---|---|
2024 | 11.99 | 12.29% |
2025 | 10.30 | 14.10% |
2026 | 8.90 | 13.59% |
2027 | 7.74 | 13.03% |
2028 | 6.99 | 9.69% |
Based on analysts' sales estimates for 2024, the Biogen stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of 2.80 and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of 2.29 .
This results in the following potential growth metrics and future valuations:
Current | 2.93 | 34.16% |
---|---|---|
2024 | 2.80 | 4.41% |
2025 | 2.84 | 1.50% |
2026 | 2.80 | 1.69% |
2027 | 2.70 | 3.35% |
2028 | 2.62 | 3.15% |
Current | 2.39 | 38.57% |
---|---|---|
2024 | 2.29 | 4.27% |
2025 | 2.32 | 1.50% |
2026 | 2.28 | 1.69% |
2027 | 2.21 | 3.35% |
2028 | 2.14 | 3.15% |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.